Factors associated with 10 years of continuous viral load suppression on HAART
Open Access
- 22 July 2016
- journal article
- research article
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 16 (1) , 1-8
Abstract
The principal goal of HAART is sustained viral load (VL) suppression resulting in immune reconstitution and improved HIV outcomes. We studied the factors associated with 10 years of continuous VL suppression on HAART in the US Military HIV Natural History Study. Participants with continuous VL suppression (CS, n = 149) were compared to those who did not have continuous viral load suppression (NCS, n = 127) for ≥10 years on HAART. Factors associated with >10 years of VL suppression were evaluated by multivariate logistic regression. Additionally, association between CS and CD4 reconstitution was analyzed with a mixed effects model. Compared to NCS participants, a lower proportion of CS participants started HAART in the early HAART era (66 vs 90 %, for years 1996–1999; p < 0.001) and had less antiretroviral use prior to HAART (37 vs 83 %; p < 0.001). At initial HAART, the median CD4 cell count was higher and VL was lower for CS compared to NCS participants (375 cells/uL [256, 499] vs 261 cells/uL [146, 400]; p < 0.001 and 4.4 log10 copies/mL [3.5, 4.9] vs 4.5 log10 copies/mL [3.8, 5.0]; p = 0.048, respectively). New AIDS events were lower during HAART (5 vs 13 %; p = 0.032) and post-HAART CD4 trajectories were greater for the CS compared to NCS group. Factors negatively associated with ≥10 years of VL suppression included log10 VL at first HAART (OR 0.61, 95 % CI 0.4, 0.92; p = 0.020) and antiretroviral use prior to HAART (OR 0.16, 95 % CI 0.06, 0.38; p < .001). Sustained VL suppression is a key to long-term health in HIV-infected patients, as demonstrated by the lower proportion of AIDS events observed 10 years after HAART initiation. The current use of more potent and well-tolerated regimens may mitigate the negative factors of pre-HAART VL and prior ARV use encountered by treatment initiated in the early HAART era.Keywords
Funding Information
- National Institute of Allergy and Infectious Disease
- National Institutes of Health
This publication has 34 references indexed in Scilit:
- Disparities in the Quality of HIV Care When Using US Department of Health and Human Services IndicatorsClinical Infectious Diseases, 2014
- Linkage, Engagement, and Viral Suppression Rates Among HIV-Infected Persons Receiving Care at Medical Case Management Programs in Washington, DCJAIDS Journal of Acquired Immune Deficiency Syndromes, 2013
- HIV Infection and the Risk of Acute Myocardial InfarctionJAMA Internal Medicine, 2013
- Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trialThe Lancet Infectious Diseases, 2012
- Projected life expectancy of people with HIV according to timing of diagnosisAIDS, 2012
- Virologic Response Differences Between African Americans and European Americans Initiating Highly Active Antiretroviral Therapy With Equal Access to CareJAIDS Journal of Acquired Immune Deficiency Syndromes, 2009
- HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysisThe Lancet, 2006
- Self-Report Measures of Antiretroviral Therapy Adherence: A Review with Recommendations for HIV Research and Clinical ManagementAIDS and Behavior, 2006
- Maximum suppression of HIV replication leads to the restoration of HIV-specific responses in early HIV diseaseAIDS, 2000
- Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapyAIDS, 2000